On 27 October 2025, China Medical System Holdings Limited announced that its subsidiary, CMS Vision International Management Limited, has entered into a distribution agreement with Novartis Pharma Services AG for Lucentis® (ranibizumab) and Beovu® (brolucizumab).
Under the agreement, CMS has the exclusive rights to import, distribute, sell and promote Lucentis® and Beovu® in the People’s Republic of China for a five-year term. Novartis will continue to be responsible for the production and supply of the products. Both Lucentis® and Beovu® are approved for marketing in China, with Lucentis® being the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China.
There are a number of ranibizumab biosimilars approved across global markets. Formycon/Teva’s FYB201/Ranivisio® was first approved in Europe in August 2022, and was developed by Bioeq (a joint venture between Formycon and Polpharma Biologics), and has been commercialised in the region in vial and PFS form, by Teva since 2022 and 2025, respectively. It was approved in the UK (in May 2022, marketed as Ongavia® by Teva), the US (in August 2022, marketed as Cimerli®, to which Sandoz acquired the marketing rights from Coherus in March 2024), Canada (in December 2023, marketed as Ranopto™ by Teva) and MENA (in March 2024, marketed as Ravegza® by MS Pharma). Other approved ranibizumab biosimilars include Samsung Bioepis’ Byooviz® (EU-approved in September 2021, FDA-approved in September 2021); Lupin’s biosimilar (being marketed in the EU by Sandoz); and STADA/Xbrane’s Ximluci® (EU-approved in November 2022).